文献速递胸部肿瘤

晚期非小细胞肺癌PD-1轴抑制剂获得性耐药的临床特征与管理

Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2018-03-22

该单中心研究纳入26例对PD-1轴抑制剂出现获得性耐药的晚期NSCLC患者,中位至耐药时间313天,耐药后2年生存率70%(95%CI 0.53-0.92)。耐药多局限于一个或两个部位,淋巴结最易受累;继续用药联合局部治疗者2年生存率达92%(95%CI 0.77-1)。

要点

  • 获得性耐药常局限于一个或两个部位,淋巴结尤为常见
  • 耐药后继续PD-1轴抑制剂并联合局部治疗可获持久获益
  • 停药后进展者再次挑战同类PD-1轴抑制剂仍可能有效

核心结论

  • PD-1轴抑制剂获得性耐药多局限于一个或两个部位,局部治疗联合继续PD-1轴抑制剂治疗可带来持久获益。
  • 淋巴结转移灶似乎是获得性耐药的易感部位。
  • 停药后出现进展者再次挑战PD-1轴抑制剂仍可导致肿瘤退缩。

研究设计与样本

  • 获得性耐药定义为初始缓解后按RECIST v1.1或免疫相关反应标准评估为疾病进展。
  • 通过临床与影像学特征对患者进行评估。

主要发现

  • 中位至获得性耐药时间为313天,耐药后2年生存率为70%(95%CI 0.53-0.92)。
  • 20例(77%)在淋巴结出现获得性耐药,其中11例为仅淋巴结进展。
  • 15例(58%)接受针对耐药部位的局部治疗,其中11例在局部治疗后继续原PD-1轴抑制剂,该15例耐药后2年生存率为92%(95%CI 0.77-1)。

关键数值与推荐

  • 获得性耐药定义:初始缓解后按RECIST v1.1或免疫相关反应标准评估为疾病进展。
  • 3例在停药并进展后再次挑战同一PD-1轴抑制剂,其中2例再次缓解。

临床怎么用

  • 对PD-1轴抑制剂初始缓解后出现寡进展(一个或两个部位)者,可考虑局部治疗并继续PD-1轴抑制剂。
  • 淋巴结进展常见,评估时应重点关注淋巴结病灶。
  • 停药后进展的部分患者可考虑再次挑战同类PD-1轴抑制剂。

局限性

  • 单中心回顾性研究,样本量仅26例。
  • 获得性耐药定义依赖RECIST v1.1或免疫相关反应标准,存在评估差异可能。
  • 未设对照组,局部治疗与继续用药的独立贡献无法区分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: With expanding indications for programmed death 1 (PD-1) axis inhibitors in non-small cell lung cancer (NSCLC), acquired resistance (AR) to these therapies is increasingly being encountered. We sought to characterize clinical patterns of AR to PD-1 axis inhibitors in patients with advanced NSCLC, and evaluate subsequent outcome and management strategies for such patients. METHODS: Patients with NSCLC who developed AR to PD-1 axis inhibitor therapy initiated between December 2009 and February 2016 at one institution were identified and examined by clinical and radiographic features. AR was defined as progressive disease after initial response by either Response Evaluation Criteria in Solid Tumors v1.1 or immune-related response criteria. RESULTS: Twenty-six patients with AR to PD-1 axis inhibitor therapy were identified and evaluated. Median time to AR was 313 days; the 2-year survival rate from AR was 70% (95% confidence interval: 0.53-0.92). Twenty patients (77%) experienced AR in lymph nodes (LNs), including 11 patients with LN-only progression. Twenty-three (88%) patients had recurrence limited to one (54%) or two (35%) sites of disease. Fourteen patients (54%) continued PD-1 axis inhibitor therapy beyond progression. Three patients were re-challenged with the same PD-1 axis inhibitor after holiday from and progression off therapy, 2 again responded. Fifteen patients (58%) received local therapy to site(s) of AR, 11 continued respective PD-1 axis inhibitor after local therapy. The 2-year survival rate from AR among these 15 patients was 92% (95% confidence interval: 0.77-1). CONCLUSIONS: Acquired resistance to PD-1 axis inhibitors is often limited to one or two sites when local therapy and continuation of PD-1 axis inhibitor therapy can result in prolonged benefit. LN metastases appear to be particularly susceptible sites to AR. When progression of disease following response occurs after holiday from PD-1 axis inhibitor, re-challenge can again lead to tumor regression.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Gettinger SN, Wurtz A, Goldberg SB, et al. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018. PMID: 29578107. doi:10.1016/j.jtho.2018.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。